Health Canada approves ONGLYZA for type 2 diabetes treatment

http://www.for-diabetes.com/health-canada-approves-onglyza-for-type-2-diabetes-treatment

ONGLYZA(TM) (saxagliptin) approval coincides with new research that shows 91 per cent of Canadians with diabetes are drifting in the management of their disease

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control – hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG)

Read More: http://www.for-diabetes.com/health-canada-approves-onglyza-for-type-2-diabetes-treatment